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Summary
 
We wish to identify developmental changes in germinal center B cells that may contribute to
their rapid growth. SHP-1 is an SH2 domain–containing phosphotyrosine phosphatase that
negatively regulates activation of B cells and other cells of hematopoietic lineages. We have
found that in all 13 EBV-negative and 11 EBV-positive Burkitt lymphomas with a nonlym-
phoblastoid phenotype, the mean concentration of SHP-1 was reduced to 5% of that of normal
B and T cells. The possibility that this diminished expression of SHP-1 was related to the ger-
minal center phenotype of Burkitt lymphomas was supported by the low to absent immunoflu-
orescent staining for SHP-1 in germinal centers, and by the inverse relationship between the
concentration of SHP-1 and the expression of the germinal center marker CD38 on purified
tonsillar B cells. In CD38-high B cells, SHP-1 concentration was 20% of that of mantle zone B
cells from the same donor. This reduction in SHP-1 is comparable to that of cells from moth-
 
eaten viable me
 
v
 
/me
 
v
 
 mice in which there is dysregulated, spontaneous signaling by cytokine
and antigen receptors. Therefore, germinal center B cells may have a developmentally regu-
lated, low threshold for cellular activation.
 
S
 
HP-1 is a phosphotyrosine phosphatase (PTPase)
 
1
 
 that
is expressed mainly in cells of hematopoietic lineages. It
is comprised of a phosphatase domain and two SH2 do-
mains which bind phosphotyrosyl peptides having the con-
sensus sequence pYXXL (1–4). Binding of phosphotyrosyl
peptides to the NH
 
2
 
-terminal SH2-domain relieves the cata-
lytic site from autoinhibition by this domain, whereas the
COOH-terminal SH2 domain serves only to promote at-
tachment of the PTPase to tyrosine phosphorylated pro-
teins (5–7). Signaling by three categories of receptors has
been shown to be negatively regulated by SHP-1: receptor
tyrosine kinases such as c-kit (8–10), CSF-1 receptor (11,
12), TrkA (13), and the EGF receptor (14, 15); cytokine
receptors such as the IL-3 receptor (16), the interferon 
 
a
 
/
 
b
 
receptor (17), and the erythropoietin receptor (18, 19); and
receptor complexes of the immune system that have sub-
units containing the immune receptor tyrosine-based acti-
vation motif (20–27). In receptor tyrosine kinases, SHP-1
suppresses signaling by dephosphorylating the activated re-
 
ceptors (8–10, 12, 14, 15). Among the cytokine receptors,
SHP-1 binds to phosphotyrosines of noncatalytic subunits
of the receptors and dephosphorylates the autocatalytic
phosphotyrosines of the associated Janus kinases (17, 19).
The immune receptor tyrosine-based activation motif fam-
ily of receptor complexes demonstrates a more diverse pat-
tern for recruiting SHP-1. In T cells, SHP-1 has been re-
ported to bind to the tyrosine kinase, ZAP-70 (20), TCR-
 
e
 
,
and CD5 (21) to inhibit signaling by the T cell receptor,
whereas in NK and B cells, membrane proteins distinct from
those of the activating receptor complex, the killer cell in-
hibitory receptor (22), Fc
 
g
 
RIIB (23), and CD22 (24–27)
bind SHP-1. Juxtapositioning of these inhibitory receptors
to the activating receptors allows SHP-1 to suppress the
stimulation of B and NK cells (22–24, 28).
The biological importance of SHP-1 in B cells has been
exemplified by analyses of motheaten (
 
me
 
/
 
me
 
) and moth-
eaten viable (
 
me
 
v
 
/
 
me
 
v
 
) mice in which expression of the PTP-
ase is impaired. In contrast to the 
 
me
 
/
 
me
 
 mouse which has
an early frameshift mutation and no detectable levels of
SHP-1, the 
 
me
 
v
 
/
 
me
 
v
 
 mouse expresses two SHP-1 proteins
that have only 10–20% normal activity (29, 30). Both strains
have elevated serum levels of IgM and expansion of the B-1
subset of B cells (31) which may reflect either excessive
stimulation through membrane immunoglobulin (mIg), the
 
1
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me
 
v
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me
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ature; tTA, tetracycline-controlled transactivator.
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IL-5 receptor which shares a common 
 
b
 
 chain with the IL-3
receptor, or both. In a model system of mice expressing
mIg specific for hen egg lysozyme (HEL) on the 
 
me
 
v
 
/
 
me
 
v
 
background, there was a lower threshold for signaling
through mIg (32). A similar abnormality has been observed
in 
 
CD22
 
2
 
/
 
2
 
 mice (33–36), consistent with CD22 inhibit-
ing B cell activation through its recruitment of SHP-1. In-
terfering with the interaction of Fc
 
g
 
RIIB and SHP-1 by de-
leting either protein also promotes B cell activation through
mIg (32, 37) suggesting that the recruitment of SHP-1 by this
receptor can suppress signaling, although the inositol poly-
phosphate 5-phosphatase SHIP may contribute to these in-
hibitory effects of Fc
 
g
 
RIIB (38).
The pivotal role of SHP-1 in determining whether ma-
ture B cells respond to antigen led us to examine its levels
during the phase of rapid, antigen-dependent expansion in
the germinal center. We find that the cellular concentra-
tion of SHP-1 is reduced in both primary and transformed
centroblasts to levels comparable or less than with those of
 
me
 
v
 
/
 
me
 
v
 
 mice, suggesting that this developmental stage of
the B cell may have hypersensitive responses to antigen or
growth factors.
 
Materials and Methods
 
Cells.
 
Cell lines were maintained in RPMI supplemented
with 10% FCS, penicillin (100 U/ml), streptomycin (100 
 
m
 
g/ml)
(GIBCO, Uxbridge, UK). Tonsillar mononuclear cells were pu-
rified by centrifugation over Ficoll–Hypaque (Pharmacia LKB
Biotechnology, Uppsala, Sweden) followed by separation into
high and low density lymphocytes by centrifugation through 30,
50, 55, and 60% Percoll gradient (Pharmacia LKB Biotechnol-
ogy). The low density population was enriched in germinal cen-
ter (GC) B cells by depleting T and follicular mantle zone B cells
using anti-CD3 UCHT-1 (a gift from Dr. Claire Hivroz, Paris,
France), anti-CD5 (Coulter Corp., Hialeh, Florida), anti-CD39
(Serotec Ltd., Oxford, UK) and anti-IgD (DAKO, Bucks, UK)
IgG1 mAbs followed by anti–mouse IgG-coated magnetic beads
(Dynabeads; Dynal, Oslo, Norway). GC cells were then purified by
sorting with a FACSVantage
 
Ò
 
 (Becton Dickinson, Oxford, UK)
after labeling cells with FITC-conjugated anti-CD19 (Coulter
Corp.) and PE-conjugated anti-CD38 mAbs (Becton Dickinson).
In some experiments, enriched GC cells were labeled with the
anti-CD77 IgM rat mAb (Immunotech, Marseilles, France) fol-
lowed by FITC-conjugated goat anti–rat IgM Ab (The Binding
Site, Birmingham, UK) and with PE-conjugated anti-CD38
IgG1 mAb in the presence of an excess of an irrelevant IgG1
mAb, MOPC21. Cells were sorted into CD38-positive, CD77-
positive (centroblasts), and CD38-positive, CD77-negative (cen-
trocytes) subpopulations. Resting CD19-positive, CD38-negative
mantle zone B cells were purified from the high density fraction
by sorting. To obtain memory B lymphocytes, cells from the high
density fraction were depleted in T and activated B cells by using
anti-CD3, anti-CD38 Ab (Becton Dickinson) and anti–mouse IgG-
coated magnetic beads. The resulting population, which was 97%
CD19-positive, was stained with an FITC-conjugated goat anti–
human IgG 
 
g
 
 chain–specific (Sigma Chemical Co., Poole, UK) and
IgG-positive cells were purified by sorting.
 
Assay of SHP-1.
 
Cell lysates were prepared at 4
 
8
 
C in buffer
containing 1% NP-40, 50 mM Tris/HCl, pH 7.5, 10 mM EDTA,
80 mM KCl, and 50 
 
m
 
M PMSF, 10 
 
m
 
g/ml leupeptin, 10 
 
m
 
g/ml
aprotinin, 1 
 
m
 
g/ml antipain, 1 
 
m
 
g/ml pepstatin A, 1 
 
m
 
g/ml chy-
mostatin (all from Sigma Chemical Co.). The particulate fraction
was removed by centrifugation at 13,000 
 
g
 
, and protein concen-
tration in the soluble lysate was assayed by the BCA protein assay
kit (Pierce, Chester, UK).
Affinity-purified anti-SHP-1 antibody was developed by im-
munizing rabbits with a glutathione-
 
S
 
 transferase (GST)-SHP-1
fusion protein (3). Immune immunoglobulin was adsorbed to and
eluted from immobilized recombinant SHP-1 that had been ren-
dered free of GST by thrombin cleavage of the GST-SHP-1 fu-
sion protein. For the ELISA assay of SHP-1 in cell lysates, the
anti-SHP-1 antibody was coated onto 96-well Nunc immuno-
plates (GIBCO) at 2.5 
 
m
 
g/ml in 50 mM carbonate buffer (pH
9.6) at 4
 
8
 
C overnight. Plates were washed in PBS containing
0.05% Tween-20 (vol/vol), blocked with 1% BSA in the same
buffer for 2 h at room temperature (RT), and sequentially incu-
bated for 1 h at RT with serial dilutions of cell lysate, biotinylated
rabbit anti-SHP-1 at 1 
 
m
 
g/ml, and horseradish peroxidase–conju-
gated streptavidin (Pierce). Plates were read at OD of 450 nm 30
min after addition of 
 
o
 
-phenylenediamine (OPD) as the substrate
(Sigma Chemical Co.). A standard curve was established using re-
combinant SHP-1 free of GST. The SHP-1 concentration in cells
was calculated as the ratio between SHP-1 concentration and to-
tal protein concentration, and expressed as percent SHP 
 
2
 
 1/to-
tal cellular protein.
For Western blot analysis, proteins from total cell lysates (150
 
m
 
g/lane) were separated by 10% SDS-PAGE, electrotransferred
to nitrocellulose membrane, blocked with 1% fatty acid–poor BSA
(Calbiochem, Nottingham, UK), and immunoblotted with the
affinity-purified rabbit anti-SHP-1 antibody followed by horse-
radish radish–conjugated mouse anti–rabbit IgG (Jackson Immu-
noresearch, Westgrove, PA). The blots were visualized with the
enhanced chemiluminescence detection system (Amersham, Lit-
tle Chalfont, UK).
For functional assay of SHP-1, 5 
 
3
 
 10
 
6
 
 cells were lysed in 1 ml
of NP-40 lysis buffer and 2 
 
m
 
g of affinity-purified anti-SHP-1
was added for 60 min at 4
 
8
 
C. Immune complexes were absorbed
with protein A (Pierce) for 60 min at 4
 
8
 
C and washed four times
with phosphatase assay buffer (20 mM imidazole, pH 7.0, 0.2% 
 
b
 
mercaptoethanol). The synthetic peptide substrate Raytide (Cal-
biochem), was labeled using 
 
g
 
-[
 
32
 
P]ATP (Amersham) and p43 abl
kinase (Calbiochem; references 1, 39). The activity of SHP-1 in
the immune complex was assayed after addition of an activating
phosphotyrosyl peptide (1 
 
m
 
g/ml) corresponding to Y843 of the
cytoplasmic domain of human CD22, and is expressed as cpm of
[
 
32
 
P]O
 
4
 
 released from the Raytide.
 
Transfections.
 
The EBV-negative Burkitt cell line DG75 was
stably transfected with a modified tetracycline-controlled transac-
tivator (tTA)-dependent expression system using the plasmids, pJEF3
encoding tTA, and the expression vector PJEF4 (40). Three
constructs were prepared with the latter vector: PJEF4–SHP-1 and
PJEF4–
 
a
 
SHP-1 by inserting SHP-1 cDNA (3) into the EcoRI
cloning site in the sense and antisense orientations, respectively,
and PJEF4–SHP-1(C453S) in which the codon for C453 in the
enzyme active site was mutated to S (USE mutagenesis kit, Phar-
macia). Cells were transfected by electroporation at 250 V using a
Bio-Rad (Hercules, CA) gene pulser. A stable line, DG75tTA, ex-
pressing tTA, was first established and selected on the basis of a
high transactivator expression when transiently supertransfected
with a tTA-dependent luciferase reporter unit (40). This line was
subsequently stably cotransfected in the presence of tetracycline
(1 
 
m
 
g/ml) with the three SHP-1 plasmids. Hygromycin- and
neomycin-resistant clones were assayed for SHP-1 expression by 
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ELISA and Western blot 24 to 48 h after withdrawal of tetracy-
cline.
 
Immunofluorescent Staining of Tonsillar Sections.
 
Tonsils taken from
patients during routine tonsillectomy were flash frozen in Cryo-
M-Bed embedding media (Bright Instrument Company Ltd.,
Huntington, UK). Serial, 5-
 
m
 
m–thick frozen sections were cut
and mounted onto poly-
 
l
 
-lysine–coated slides, air dried, perme-
abilized, and fixed in cold acetone/methanol (50/50% vol/vol)
for 15 min, washed in Tris-buffered saline, blocked in 10% FCS,
and incubated with affinity-purified rabbit anti-SHP-1 or rabbit
anti-GST, and either anti-CD38 or anti-CD19 mAbs for 1 h at
RT, followed by FITC-conjugated F(ab
 
9
 
)
 
2
 
 goat anti–rabbit Ig
(Jackson Immunoresearch) and TRITC-conjugated goat F(ab
 
9
 
)
 
2
 
anti–mouse Ig (Sigma Chemical Co.). The stained sections were
examined by fluorescent microscopy. Images were captured using
smartCapture software (Digital Scientific) from a cooled CCD
camera (Photometrics KAF1400) mounted on a Zeiss Axioskop
microscope equipped with an automated filter wheel, triple band-
pass filter and a 20
 
3
 
 objective (total magnification 200
 
3
 
).
TRITC and FITC images were captured separately as black and
white 24-bit images, merged, and displayed as a final color 24-bit
picture. All image processing was performed on a Macintosh
Quadra 840AV using IPLab Software.
 
Results
 
Levels of Expression of SHP-1 among Lymphocytes.
 
We ini-
tially compared the amount of SHP-1 in six human B cell
lines by Western blot analysis and found that the PTPase
was expressed at different levels among these lines (Fig. 1).
Although SHP-1 was easily detected in lysates from two
EBV-immortalized lymphoblastoid cell lines (LCLs),
WW2LCL and JY, it was reduced in three of three Burkitt
lymphomas: Ramos, Daudi, and WW2BL. BJAB, a B lym-
phoma line morphologically resembling EBV-negative Bur-
kitt lymphoma but lacking the characteristic chromosomal
translocation that involves 
 
c-myc
 
 (41), expressed higher levels
of SHP-1. To quantitatively assay SHP-1 concentration in
cell lysates, we developed an ELISA using an affinity-purified
polyclonal rabbit antibody specific for SHP-1 as both the
capture and detecting antibody, and recombinant SHP-1 as
the standard. The measurement of SHP-1 confirmed the
results of the semiquantitative Western blots, indicating
that in the three Burkitt lymphomas with 
 
c-myc
 
 transloca-
tions, the SHP-1 intracellular concentrations were reduced
relative to the levels in the EBV-immortalized lines (Fig. 1).
We assayed the concentration of SHP-1 in a large panel
of cells, including primary T and B cells, granulocytes, EBV-
immortalized LCLs from healthy individuals, EBV-nega-
tive and -positive Burkitt lymphomas, and LCLs established
with normal B cells from patients with Burkitt lymphoma
(Fig. 2). The concentration of SHP-1 in normal primary T
and B cells purified from tonsils of five individuals ranged
between 0.04 and 0.14% (mean 
 
5
 
 0.085%) of total cellular
protein (Fig. 2). Activation of B cells in vitro with poke-
weed mitogen did not alter the levels of SHP-1 (data not
shown). Granulocytes purified from the peripheral blood of
five individuals had similar concentrations of SHP-1 (mean 
 
5
 
0.062% of total cellular protein), as did eight LCL lines
from normal individuals (mean 
 
5
 
 0.070% of total cellular
protein). In 13 of 13 EBV-negative Burkitt lymphoma lines,
SHP-1 levels were reduced by one to three orders of mag-
nitude relative to the levels in normal lymphocytes (mean 
 
5
 
0.004% of total cellular protein). Group I/II EBV-positive
Burkitt lines, which have retained the original tumor bi-
opsy phenotype and which morphologically resemble EBV-
negative lines, had comparably reduced concentrations of
SHP-1 (mean 
 
5
 
 0.005% of total cellular protein). In contrast,
the levels of SHP-1 were normal in four of four group III
EBV-positive Burkitt lymphomas (mean 
 
5
 
 0.077% of total
cellular protein) which resemble LCLs morphologically, by
surface phenotype, and by EBV gene expression (42). In
the seven Burkitt lines that had paired LCLs established from
normal B cells of these individuals, the lymphomas had re-
duced levels of SHP-1 (mean 
 
5
 
 0.003% of total cellular
protein), whereas the LCLs (mean 
 
5
 
 0.094% of total cellu-
lar protein) did not differ from normal B cells or from the
cell lines established from healthy individuals.
The apparent reversion to normal of SHP-1 levels in EBV-
infected Burkitt lymphomas in association with an LCL
phenotype suggested that the expression of the PTPase could
be modulated. This possibility was demonstrated by stimu-
lating the EBV-negative Burkitt line, Ramos, and the
EBV-positive lines Daudi and WW2BL, with either phor-
bol ester (PMA) or polyclonal antibody to IgM. In Ramos and
Daudi, both treatments caused time-dependent increases of
10–50-fold in the cellular concentration of SHP-1, whereas
in the WW2BL line, only PMA was effective because these
cells do not express mIg (Fig. 3). Additional experiments with
the Ramos line showed that the surface markers characteristic
of Burkitt lymphomas, CD38 and CD77, were unchanged af-
ter mIgM ligation, but that the ratio of CD19 to CD22 was
inverted due to an increase in CD22 and a decrease in cell
surface CD19 (data not shown). As previously reported (43),
stimulation of all three Burkitt lymphomas caused apoptosis
(not shown).
 
Transfection of a Burkitt Lymphoma Line with Plasmids Permit-
ting Tetracycline-regulated Expression of SHP-1.
 
To investigate
the biological effects of normalizing the cellular concentra-
tion of SHP-1 by a means that is independent of cellular
stimulation, we stably transfected the EBV-negative Burkitt
line, DG75, with plasmids directing tetracycline-suppress-
ible expression of wild-type SHP-1, SHP-1 in which the ac-
tive site cysteine is replaced with serine, and SHP-1 in the
Figure 1. Western blot analy-
sis of SHP-1 in lysates from the
Burkitt lymphomas, Ramos,
Daudi and WW2BL, the LCLs,
WW2LCL and JY, and the B
lymphoma BJAB. The numbers
at the bottom of the gel repre-
sent the concentration of SHP-1
in the cellular lysates as deter-
mined by ELISA. 
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antisense orientation. Removal of tetracycline from the
medium led to a 10–40-fold increase over 48 h in the con-
centration of wild-type SHP-1 in the clone S9.26, and of
SHP-1–inactive mutant in the CS2.30 clone; no increase
occurred with the AS14.28 clone transfected with the anti-
sense construct (Fig. 4). Analysis by Western blot indicated
that both forms of SHP-1 comigrated with the PTPase ex-
pressed by LCLs (data not shown). Assay of phosphotyrosine
phosphatase activity revealed that immunoprecipitates of
SHP-1 from uninduced and induced S9.26 clones released
112 cpm and 2,022 cpm, respectively, from [
 
32
 
P]O
 
4
 
-labeled
Raytide. This level of PTPase activity in the lysate of in-
duced S9.26 cells was comparable to that of the WW2LCL
line, which was 2,144 cpm. The CS2.30 clone, whether
grown in the presence (128 cpm) or absence (148 cpm) of
tetracycline, showed little SHP-1 activity.
We examined the effects of elevating SHP-1 on the
membrane expression of IgM, apoptosis, and DNA synthe-
sis. The induction of SHP-1 expression after removal of
tetracycline from S9.26 cells was associated with twofold
increase in mIgM, as assessed by flow cytometry of cells
stained with monoclonal anti-IgM (Fig. 4). In three repli-
cate experiments with this clone, similar increases of two- to
threefold in mIgM were observed, and inducibly express-
ing SHP-1 in an additional, independent clone was also as-
sociated with increased mIgM. There was no change in the
levels of three other membrane proteins, CD19, CD22,
and CD38 (not shown). This response to SHP-1 required
its phosphatase activity because comparable increases in the
protein concentration of the SHP-1–inactive mutant in clone
CS2.30 were not accompanied by changes in mIgM ex-
pression (Fig. 4). The clone expressing the antisense plas-
Figure 2. Concentration of
SHP-1 in primary and trans-
formed human cells as deter-
mined by ELISA. The closed
symbols designate EBV-positive
Burkitt lymphomas. The shaded
area represents the mean 6 1 SD
of the SHP-1 levels in normal B
and T cells.
Figure 3. Kinetics of upregu-
lation of SHP-1 expression in
untreated Burkitt lymphomas
(open squares), in lymphomas
stimulated with 20 ng/ml PMA
(closed squares), or with 5 mg/ml
polyclonal goat F(ab9)2 anti-IgM
(closed circles). †.70% of WW2BL
cells had undergone apoptosis af-
ter 72 h of PMA treatment.1579 Delibrias et al.
mid also showed no change in mIgM. We also examined
the effect of elevating SHP-1 on the Ca21 response induced
by ligating mIgM, but found no change, perhaps because
the level of CD22 is only 2% that of primary, mantle zone
B cells, which would prevent the recruitment of SHP-1 to
the antigen receptor complex (24, 33–36).
In contrast to this effect of restoring SHP-1 levels on
mIgM, there was no alteration in the frequency of cells un-
dergoing apoptosis during culture in 10% FCS when as-
sayed by staining with annexin V and propidium iodide
(not shown). Furthermore, the incorporation of [3H]thy-
midine by cells which had normalized their SHP-1 level was
the same as that of cells in which low SHP-1 was main-
tained by the presence of tetracycline (not shown). This clone
did undergo apoptosis in response to ligating mIgM; 37%
of cells were annexin V–positive, propidium iodide–nega-
tive with anti-IgM at 48 h, compared to 12% without anti-
IgM. At least two other experiments with the S9.26 clone
also showed no effect of induced SHP-1 on apoptosis and
DNA replication. In addition, similar results were observed
with three other clones. Therefore, low SHP-1 in the DG75
Burkitt lymphoma contributes to the diminished expression
Figure 5. Analysis of SHP-1 expression in tonsillar GCs by immunofluorescent microscopy. A–C are photomicrographs of a single section stained with
FITC-conjugated anti-SHP-1 (A), TRITC-conjugated anti-CD38 (B), and a computor generated superimposition of these two images (C). D–F are
photomicrographs of an adjacent section stained with FITC-conjugated anti-SHP-1 (D), TRITC-conjugated anti-CD19 (E), and a computer generated
superimposition of these two images (F). Magnification is 200.
Figure 4. Effects of inducing SHP-1 on the quantitative expression of
mIgM in three DG75 Burkitt lymphoma clones transfected with tTA-
regulated plasmids encoding wild-type SHP-1 (S9.26), the phosphatase-
inactive C453S mutant SHP-1 (CS2.30), and SHP-1 cDNA in the anti-
sense orientation (AS14.2), respectively. The coexpression of a plasmid
for tTA enables tetracycline to suppress transcription of the SHP-1 con-
structs. After culture of cells in the presence (open symbols) or absence
(closed symbols) of tetracycline, SHP-1 levels were measured by ELISA and
mIgM expression by FACSÒ analysis of cells stained with a monoclonal
anti-IgM antibody.1580 SHP-1 in Burkitt Lymphomas and Germinal Center B Lymphocytes
of mIgM on these cells, but apparently not to their growth or
viability in tissue culture.
Diminished Expression of SHP-1 in GC B Cells. Burkitt
lymphomas exhibit a centroblast phenotype (44) and can be
induced to mutate their immunoglobulin genes in vitro
(45), the defining functional characteristic of the GC B cell.
Thus, the low abundance of SHP-1 in these cell lines could
reflect the phenotype of GC B cells rather than being a
consequence of transformation. To investigate the expres-
sion of SHP-1 in normal GC cells, frozen tonsil sections
were stained for SHP-1 and the GC B cell membrane pro-
tein, CD38, or for SHP-1 and the pan–B cell membrane
protein, CD19. Cells in the mantle zone stained brightly
for SHP-1, but the PTPase was diminished or absent in the
CD38-positive GC cells (Fig. 5). Superimposition of the
two images confirmed that no cells expressing high CD38
were positive for SHP-1. Staining of an adjacent section for
SHP-1 and CD19 demonstrated that CD19 was distributed
equally among mantle zone and GC B cells, but again that
SHP-1 was predominantly localized to mantle zone B cells.
We also quantitated SHP-1 expression by ELISA in pu-
rified GC B cells. Total CD38- and CD19-positive B cells
that had been purified from five tonsils had SHP-1 concen-
tration that ranged from 31 to 36% (mean 33%) of the con-
centration in CD38-negative, CD19-positive cells. GC B
cells appeared to vary according to the intensity with which
they stained for CD38 (Fig. 5). Therefore, we sorted GC B
cells into CD38-high and -low populations, and compared
their levels of SHP-1 to the levels in CD38-negative B
cells. There was an inverse relationship between CD38 ex-
pression and SHP-1 content, with the highest CD38 ex-
pressing cells having a SHP-1 level that was only 20% that
of CD38-negative cells (Fig. 6). CD38-positive B cells were
also sorted on the basis of CD77 expression and assayed for
SHP-1; CD77-positive and -negative GC B cells had iden-
tical and diminished levels of SHP-1, indicating that both
centroblasts and centrocytes downregulate the PTPase (data
not shown). In two of two experiments, CD38-negative,
IgG-positive, CD19-positive B cells had the same concen-
tration of SHP-1 as did resting, CD38-negative, CD19-
positive B cells purified from the same donors (data not
shown), suggesting that SHP-1 levels return to normal when
GC cells differentiate into memory B cells.
Discussion
We have shown that the cellular concentration of SHP-1
is diminished in primary and transformed B cells exhibiting
a GC phenotype, and in B cells anatomically residing in the
GC. The level to which SHP-1 is reduced in these cells is
comparable to the reduction observed in hematopoietic cells
of the mev/mev mouse in which there is dysregulated signal-
ing through all three classes of receptors that are potentially
inhibited by this PTPase (29, 30). The return of SHP-1
levels to normal in the memory B cell indicates that this
suppression of SHP-1 is characteristic for the centroblast/
centrocyte, perhaps reflecting a requirement at this stage of
B cell development for a lower threshold for signaling via
certain cytokine receptors and mIg.
These studies were initiated by the finding of low SHP-1
in all EBV-negative Burkitt lymphomas and all EBV-positive
Burkitt lymphomas that have retained the original tumor
biopsy phenotype, which led us to consider the possibility
that relief from the inhibitory function of this PTPase may
contribute to the growth or viability of these tumors. The
constitutive expression of c-myc alone is associated with the
induction of p53, cell cycle arrest, and apoptosis (46–48).
These effects can be blocked by signaling through growth fac-
tor receptors that are subject to inhibition by SHP-1 (46, 49).
Thus, we considered the possibility that low SHP-1 in Bur-
kitt lymphomas might have permitted spontaneous signaling
through a cytokine receptor that rescued cells from c-myc–
induced apoptosis. However, we were not able to demon-
strate that normalizing SHP-1 levels in the DG75 Burkitt
lymphoma altered growth or viability, even in the presence
of reduced concentrations of FCS (not shown). We cannot
exclude the possibility that this line had accumulated addi-
tional mutations during its long-term tissue culture which
had rendered it insensitive to SHP-1.
A biological effect of inducing SHP-1 was observed, which
was an increase in mIgM expression in the DG75 clone ex-
pressing active PTPase, but not in the clone expressing in-
active enzyme (Fig. 4). Low SHP-1 in the mev/mev mouse
is also associated with low mIgM expression (32). It was
suggested that this change was caused by spontaneous sig-
naling through the dysregulated antigen receptor, by anal-
ogy to the diminished mIgM in HEL, anti-HEL double trans-
genic mice (50). We have not determined if the effects of
elevating SHP-1 in the Burkitt lymphoma reflects decreased
catabolism of mIgM or its increased biosynthesis, although
the 24-h delay in mIgM expression, relative to induced
SHP-1, would be consistent with enhanced synthesis.
Figure 6. Inverse correlation between the levels of SHP-1 and CD38
expression in GC B cells. (A) CD19-positive, CD38-negative B cells
(R2) were purified by sorting from high density tonsillar B cells (top).
CD38-high (R3) and CD38-low (R4) B cells were purified by sorting
from low density, CD39-negative tonsillar B cells (bottom). (B) The ex-
pression of SHP-1 and CD38 in the R2, R3, and R4 subpopulations of
sorted tonsillar B cells was determined by ELISA and flow cytometry, re-
spectively.1581 Delibrias et al.
That SHP-1 levels may vary with stages of cellular differ-
entiation has also been shown in studies finding that PMA
induction of HL-60 cells to a more macrophage-like phe-
notype was accompanied by a two- to threefold increase in
the concentration of the PTPase (51, 52). However, our
study is the first to demonstrate a reversible downregulation
of SHP-1 expression coincident with a specific phase of
cellular differentiation. Low SHP-1 may facilitate the sig-
nals required for GC clonal expansion, isotype switching,
hypermutation, and selection for high affinity memory B
cells. In this respect, it is interesting that two receptors that
induce differentiation of primary B cells in vitro into CD38-
positive cells, mIg, and the type I interferon receptor, are both
regulated by SHP-1 (53). Future studies should determine
whether these or other receptors are the beneficiaries of this
developmentally regulated release from inhibition by this
PTPase.
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